Hims & Hers shares dropped over 10% as the FDA declared the active ingredient in weight loss drugs Mounjaro and Zepbound is no longer in shortage. The company provides access to GLP-1 injections. Vertex Pharmaceuticals fell around 13% after announcing Phase 2 study results for suzetrigine, a pain signal inhibitor. While placebo recipients showed similar pain reduction, the company plans to proceed with Phase 3 trials. Palantir Technologies rose 4% following an extended partnership with the U.S.
Army, valued at $400.7 million for up to four years with a potential ceiling of $618.9 million. Darden Restaurants surged over 15% on better-than-expected same-store sales growth at Olive Garden and LongHorn Steakhouse. The company also increased its full-year revenue guidance to $12.1 billion. Accenture gained about 7% after exceeding fiscal first-quarter revenue expectations and raising its full-year guidance to 4% to 7% revenue growth. Finally, Micron Technology plummeted over 16% due to weaker-than-expected fiscal second-quarter guidance, attributed to weaker consumer-oriented markets. CEO Sanjay Mehrotra expects a return to growth in the second half of the fiscal year
Nederland Laatste Nieuws, Nederland Headlines
Similar News:Je kunt ook nieuwsberichten lezen die vergelijkbaar zijn met deze die we uit andere nieuwsbronnen hebben verzameld.
Bron: Investingcom - 🏆 450. / 53 Lees verder »